Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0006 USD | -25.00% | 0.00% | -60.00% |
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Biopharma Services
76.7
%
| - | - | 0 | 76.7 % | - |
Patient Testing Service
23.3
%
| - | - | 0 | 23.3 % | - |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 1 | 100.0 % | 1 | 100.0 % | +6.85% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Faith Zaslavsky
CEO | Chief Executive Officer | 49 | 22-12-04 |
Director of Finance/CFO | 43 | 08-12-31 | |
Michael Ruxin
CTO | Chief Tech/Sci/R&D Officer | 78 | 17-12-31 |
Trevor McCartney
IRO | Public Communications Contact | - | 19-02-28 |
Michael Vallone
PRN | Corporate Officer/Principal | - | 23-01-08 |
Mattia Cremona
PRN | Corporate Officer/Principal | - | 22-11-06 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jeffrey Busch
CHM | Chairman | 66 | 20-06-17 |
Michael Ruxin
CTO | Chief Tech/Sci/R&D Officer | 78 | 17-12-31 |
Director of Finance/CFO | 43 | 08-12-31 | |
Danica Holley
BRD | Director/Board Member | 51 | 22-04-03 |
Yvonne Fors
BRD | Director/Board Member | 52 | 20-06-17 |
Matthew Schwartz
BRD | Director/Board Member | 50 | 22-04-04 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 500 | 0 | 0 | 17.39 % |
Stock B | 0 | 1,000 | 0 | 0 | |
Stock C | 1 | 6,151,499,919 | 1,069,660,735 ( 17.39 %) | 0 |
Company contact information
Sector
Sales per Business
1st Jan change | Capi. | |
---|---|---|
-60.00% | 3.69M | |
+7.52% | 113B | |
+11.38% | 106B | |
-12.64% | 22.22B | |
+0.44% | 22.27B | |
-4.18% | 19.43B | |
-37.85% | 17.87B | |
-8.58% | 17.24B | |
+37.41% | 12.52B | |
-23.95% | 8.34B |
- Stock Market
- Equities
- THER Stock
- Company Theralink Technologies, Inc.